In clinical practice, management of MSI-H colorectal cancer patients should incorporate CTC functional characteristics (e.g., PD-L1 expression or CEACAM5 mRNA positivity) and dynamic monitoring of CTC count changes pre- and postoperatively as well as before and after adjuvant therapy to optimize personalized management strategies. This evidence concerns the gene CD274 and colorectal cancer.